The evolving role of immuno‐oncology for the treatment of head and neck cancer

Strome, Arianna; Zhang, Xiaoyu; Strome, Scott E.

doi:10.1002/lio2.235

Cited by 3 publications

(2 citation statements)

References 120 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…28 Immuno-oncological treatments have resulted in dramatic responses in some cases, but overall response rates have nonetheless been disappointingly low. 29,30 The effect of immuno-oncological treatments on long-term QOL is still unknown. Further information and developments in robotic surgery and immuno-oncological treatments are likely to change the treatment algorithms of OPSCC in the future.…”

Section: Discussionmentioning

confidence: 99%

Long‐term Quality of Life After Treatment of Oropharyngeal Squamous Cell Carcinoma

et al. 2020

View full text Add to dashboard Cite

Objectives: To analyze the long-term quality of life (QOL) among oropharyngeal squamous cell carcinoma (OPSCC) survivors. Study Design: Retrospective chart analysis and patient response to European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, Core Module (EORTC QLQ-C30), Head and Neck Module (EORTC QLQ-H&N35), and M.D. Anderson Dysphagia Inventory (MDADI) survey questionnaires. Methods: All survivors of OPSCC diagnosed and treated between 2000 and 2009 in Finland were included. There were 263 survivors (44.2% of all curatively treated patients), of which a total of 164 participated in this study (62.4%). Median follow-up was 11.79 years (range = 8.59-18.53 years, interquartile range [IQR] = 4.64 years). The mean age of the participants was 67.9 years (standard deviation = 8.0 years) at QOL follow-up. Results: Most survivors reported a good QOL. The EORTC QLQ-C30 global health status median was 75.00 (IQR = 31.25). The single modality treatment group had significantly better QOL outcomes than the combined treatment group. Nonsmokers and previous smokers had significantly better QOL outcomes than patients who smoked at the time of diagnosis. A history of heavy alcohol use resulted in significantly worse QOL outcomes. The p16-positive cancer patients had significantly better QOL outcomes than p16-negative patients. Percutaneous endoscopic gastrostomy (PEG) tube-dependent patients reported a significantly worse QOL than patients without a PEG tube. Conclusions: Long-term QOL in OPSCC survivors is generally good. In line with previous literature, single modality treatment was superior to combined treatment in long-term QOL outcomes, and it should be pursued whenever possible.

show abstract

Section: Discussionmentioning

confidence: 99%

Long‐term Quality of Life After Treatment of Oropharyngeal Squamous Cell Carcinoma

et al. 2020

View full text Add to dashboard Cite

show abstract

“…A few targets such as EGFR and CD44v6 have been evaluated in HNSCC (260,261). Therapeutic Abs targeting EGFR showed promising outcomes in HNSCC treatment (262). Hence, ImmunoPET can be a valuable approach for diagnosis, treatment response prediction, and RIT planning in this group of cancers (46,(263)(264)(265)(266).…”

Section: Head and Neck Squamous Cell Carcinoma (Hnscc)mentioning

confidence: 99%

ImmunoPET: Antibody-Based PET Imaging in Solid Tumors

et al. 2022

View full text Add to dashboard Cite

Immuno-positron emission tomography (immunoPET) is a molecular imaging modality combining the high sensitivity of PET with the specific targeting ability of monoclonal antibodies. Various radioimmunotracers have been successfully developed to target a broad spectrum of molecules expressed by malignant cells or tumor microenvironments. Only a few are translated into clinical studies and barely into clinical practices. Some drawbacks include slow radioimmunotracer kinetics, high physiologic uptake in lymphoid organs, and heterogeneous activity in tumoral lesions. Measures are taken to overcome the disadvantages, and new tracers are being developed. In this review, we aim to mention the fundamental components of immunoPET imaging, explore the groundbreaking success achieved using this new technique, and review different radioimmunotracers employed in various solid tumors to elaborate on this relatively new imaging modality.

show abstract